Apex Molecular Limited

POWER SEARCH PRICING

SOLUTIONS

apex molecular limited Company Information

Company Number

06596885

Next Accounts

Feb 2026

Directors

Peter Jackson

Thomas Screen

View All

Shareholders

the gm & life sciences fund lp

peter jackson pilgrim sipp

View All

Group Structure

View All

Industry

Research and experimental development on biotechnology

Registered Address

block 19 alderley park, mereside, alderley edge, cheshire, SK10 4TG

Website

http://yprotech.com

apex molecular limited Estimated Valuation

£5.4m

Pomanda estimates the enterprise value of APEX MOLECULAR LIMITED at £5.4m based on a Turnover of £3.3m and 1.61x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Apex Molecular Limited is a live company located in alderley edge, SK10 4TG with a Companies House number of 06596885. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in May 2008, it's largest shareholder is the gm & life sciences fund lp with a 22.5% stake. Apex Molecular Limited is a established, small sized company, Pomanda has estimated its turnover at £3.3m with healthy growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Apex Molecular Limited a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 3 areas for improvement. Company Health Check FAQs

Health Rating4.5out of 5

3 Strong

5 Regular

3 Weak

Size

annual sales of £3.3m, make it in line with the average company (£3.9m)

Growth

3 year (CAGR) sales growth of 12%, show it is growing at a similar rate (13.4%)

EXPORT

Apex Molecular Limited's latest turnover from May 2024 is estimated at £3.3 million and the company has net assets of £1.6 million. According to their latest financial statements, Apex Molecular Limited has 38 employees and maintains cash reserves of £1.2 million as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	May 2024	May 2023	May 2022	May 2021	May 2020	May 2019	May 2018	May 2017	May 2016	May 2015	May 2014	May 2013	May 2012	May 2011	May 2010
Turnover	3,341,051	3,657,473	3,290,344	2,359,701	1,874,575	1,247,168	870,841	533,956	521,878	388,596	825,747	212,456	167,261	14,645	12,189
Other Income Or Grants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cost Of Sales	1,469,936	1,660,777	1,608,351	1,140,909	904,482	586,208	392,961	254,330	275,212	208,475	425,459	20,510	17,425	7,150	4,466
Gross Profit	1,871,115	1,996,695	1,681,993	1,218,792	970,093	660,960	477,880	279,626	246,666	180,121	400,288	191,946	149,836	7,495	7,723
Admin Expenses	2,067,722	1,480,930	1,113,832	753,577	860,919	491,309	390,960	510,333	602,734	268,554	313,118	250,302	207,406	15,387	11,640
Operating Profit	-196,607	515,765	568,161	465,215	109,174	169,651	86,920	-230,707	-356,068	-88,433	87,170	-58,356	-57,570	-7,892	-3,917
Interest Payable	456	16,633	20,410	8,234	117	100	1,625	1,563	0	0	0	0	0	0	0
Interest Receivable	69,567	61,106	10,840	604	339	1,795	588	121	656	750	421	0	0	83	26
Pre-Tax Profit	-127,496	560,239	558,590	457,585	109,396	171,346	85,883	-232,148	-355,412	-87,683	87,591	-58,356	-57,570	-7,809	-3,891
Tax	0	-140,060	-106,132	-86,941	-20,785	-32,556	-16,318	0	0	0	-18,394	0	0	0	0
Profit After Tax	-127,496	420,179	452,458	370,644	88,611	138,790	69,565	-232,148	-355,412	-87,683	69,197	-58,356	-57,570	-7,809	-3,891
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retained Profit	-127,496	420,179	452,458	370,644	88,611	138,790	69,565	-232,148	-355,412	-87,683	69,197	-58,356	-57,570	-7,809	-3,891
Employee Costs	3,132,042	3,566,078	2,779,669	2,232,395	1,626,560	1,182,908	932,102	461,573	452,374	275,378	472,945	155,010	105,369	51,388	50,468
Number Of Employees	38	47	38	32	24	18	15	8	8	5	9	3	2	1	1
EBITDA*	13,709	734,916	693,919	529,874	149,482	188,548	97,589	-214,973	-344,355	-84,860	91,777	-58,356	-57,570	-7,892	-3,917

* Earnings Before Interest, Tax, Depreciation and Amortisation

	May 2024	May 2023	May 2022	May 2021	May 2020	May 2019	May 2018	May 2017	May 2016	May 2015	May 2014	May 2013	May 2012	May 2011	May 2010
Tangible Assets	152,305	335,933	413,780	161,118	118,059	86,406	16,658	24,883	32,611	16,368	11,742	11,972	6,577	0	7,200
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments & Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Debtors (Due After 1 year)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Fixed Assets	152,305	335,933	413,780	161,118	118,059	86,406	16,658	24,883	32,611	16,368	11,742	11,972	6,577	0	7,200
Stock & work in progress	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Debtors	465,469	420,990	345,656	315,279	254,265	143,587	29,941	56,293	48,306	68,674	160,716	3,972	4,024	0	0
Group Debtors	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Misc Debtors	187,205	192,639	232,453	133,292	103,027	161,335	127,326	81,576	68,519	0	0	0	0	0	0
Cash	1,236,916	1,413,259	1,302,564	865,362	343,439	334,200	144,402	90,700	6,444	255,886	44,172	124,363	19,297	22,800	10,504
misc current assets	0	0	0	0	0	0	0	0	0	0	0	0	3,035	360	218
total current assets	1,889,590	2,026,888	1,880,673	1,313,933	700,731	639,122	301,669	228,569	123,269	324,560	204,888	128,335	26,356	23,160	10,722
total assets	2,041,895	2,362,821	2,294,453	1,475,051	818,790	725,528	318,327	253,452	155,880	340,928	216,630	140,307	32,933	23,160	17,922
Bank overdraft	5,353	2,756	8,540	1,872	866	2,964	0	0	0	0	0	0	0	0	0
Bank loan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Trade Creditors	82,041	151,350	376,887	131,433	84,239	62,433	75,858	118,141	93,732	55,732	58,515	51,389	16,228	4,860	11,813
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other short term finances	0	0	101,013	60,390	0	0	0	0	0	0	0	0	0	0	0
hp & lease commitments	34,188	51,531	0	0	0	0	0	0	0	0	0	0	0	0	0
other current liabilities	276,266	351,453	252,147	175,616	105,235	99,245	92,180	50,420	35,874	0	0	0	2,475	0	0
total current liabilities	397,848	557,090	738,587	369,311	190,340	164,642	168,038	168,561	129,606	55,732	58,515	51,389	18,703	4,860	11,813
loans	0	0	204,502	206,834	0	0	0	50,000	0	0	0	0	0	0	0
hp & lease commitments	0	34,188	0	0	0	0	0	0	0	0	0	0	0	0	0
Accruals and Deferred Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
other liabilities	0	0	0	0	100,188	121,235	45,833	0	0	0	0	0	0	0	0
provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
total long term liabilities	0	34,188	204,502	206,834	100,188	121,235	45,833	50,000	0	0	0	0	0	0	0
total liabilities	397,848	591,278	943,089	576,145	290,528	285,877	213,871	218,561	129,606	55,732	58,515	51,389	18,703	4,860	11,813
net assets	1,644,047	1,771,543	1,351,364	898,906	528,262	439,651	104,456	34,891	26,274	285,196	158,115	88,918	14,230	18,300	6,109
total shareholders funds	1,644,047	1,771,543	1,351,364	898,906	528,262	439,651	104,456	34,891	26,274	285,196	158,115	88,918	14,230	18,300	6,109

	May 2024	May 2023	May 2022	May 2021	May 2020	May 2019	May 2018	May 2017	May 2016	May 2015	May 2014	May 2013	May 2012	May 2011	May 2010
Operating Activities
Operating Profit	-196,607	515,765	568,161	465,215	109,174	169,651	86,920	-230,707	-356,068	-88,433	87,170	-58,356	-57,570	-7,892	-3,917
Depreciation	210,316	219,151	125,758	64,659	40,308	18,897	10,669	15,734	11,713	3,573	4,607	0	0	0	0
Amortisation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax	0	-140,060	-106,132	-86,941	-20,785	-32,556	-16,318	0	0	0	-18,394	0	0	0	0
Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Debtors	39,045	35,520	129,538	91,279	52,370	147,655	19,398	21,044	48,151	-92,042	156,744	-52	4,024	0	0
Creditors	-69,309	-225,537	245,454	47,194	21,806	-13,425	-42,283	24,409	38,000	-2,783	7,126	35,161	11,368	-6,953	11,813
Accruals and Deferred Income	-75,187	99,306	76,531	70,381	5,990	7,065	41,760	14,546	35,874	0	0	-2,475	2,475	0	0
Deferred Taxes & Provisions	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash flow from operations	-169,832	433,105	780,234	469,229	104,123	1,977	61,350	-197,062	-318,632	4,399	-76,235	-25,618	-47,751	-14,845	7,896
Investing Activities
capital expenditure	-26,688	-141,304	-378,420	-107,718	-71,961	-88,645	-2,444	-8,006	-27,956	-8,199	-4,377	-5,395	-6,577	7,200	-7,200
Change in Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash flow from investments	-26,688	-141,304	-378,420	-107,718	-71,961	-88,645	-2,444	-8,006	-27,956	-8,199	-4,377	-5,395	-6,577	7,200	-7,200
Financing Activities
Bank loans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group/Directors Accounts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Short Term Loans	0	-101,013	40,623	60,390	0	0	0	0	0	0	0	0	0	0	0
Long term loans	0	-204,502	-2,332	206,834	0	0	-50,000	50,000	0	0	0	0	0	0	0
Hire Purchase and Lease Commitments	-51,531	85,719	0	0	0	0	0	0	0	0	0	0	0	0	0
other long term liabilities	0	0	0	-100,188	-21,047	75,402	45,833	0	0	0	0	0	0	0	0
share issue	0	0	0	0	0	196,405	0	240,765	96,490	214,764	0	133,044	53,500	20,000	10,000
interest	69,111	44,473	-9,570	-7,630	222	1,695	-1,037	-1,442	656	750	421	0	0	83	26
cash flow from financing	17,580	-175,323	28,721	159,406	-20,825	273,502	-5,204	289,323	97,146	215,514	421	133,044	53,500	20,083	10,026
cash and cash equivalents
cash	-176,343	110,695	437,202	521,923	9,239	189,798	53,702	84,256	-249,442	211,714	-80,191	105,066	-3,503	12,296	10,504
overdraft	2,597	-5,784	6,668	1,006	-2,098	2,964	0	0	0	0	0	0	0	0	0
change in cash	-178,940	116,479	430,534	520,917	11,337	186,834	53,702	84,256	-249,442	211,714	-80,191	105,066	-3,503	12,296	10,504

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for apex molecular limited. Get real-time insights into apex molecular limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for apex molecular limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in SK10 area or any other competitors across 12 key performance metrics.

APEX MOLECULAR LIMITED group structure

Apex Molecular Limited has no subsidiary companies.

Ultimate parent company

APEX MOLECULAR LIMITED

06596885

APEX MOLECULAR LIMITED Shareholders

the gm & life sciences fund lp	22.53%
peter jackson pilgrim sipp	9.62%
reaxa ltd	9.62%
hugh sykes	5.85%
share nominees limited	4.53%
university of leeds	4.43%
blackley (holdings) ltd	4.36%
ian grundy	4.29%
wcs nominees limited	4.18%
richard parry	3.05%

Apex Molecular Limited currently has 5 directors. The longest serving directors include Dr Peter Jackson (May 2008) and Dr Thomas Screen (Jun 2011).

officer	country	age	start	end	role
Dr Peter Jackson	United Kingdom	62 years	May 2008	-	Director
Dr Thomas Screen	England	50 years	Jun 2011	-	Director
Dr Anthony Flinn		66 years	Sep 2016	-	Director
Dr Stuart Brown	England	51 years	Dec 2016	-	Director
Mr Mark Warburton	United Kingdom	74 years	Nov 2018	-	Director

P&L

May 2024

turnover

3.3m

-9%

operating profit

-196.6k

gross margin

56.1%

+2.59%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

May 2024

net assets

1.6m

-0.07%

total assets

-0.14%

cash

1.2m

-0.12%

net assets

Total assets minus all liabilities

Similar Companies

revivocell limited

2.5

qa consultancy limited

2.5

bivictrix therapeutics limited

biorelate limited

3.5

livie biopesticides limited

1.5

company number

06596885

Type

Private limited with Share Capital

industry

72110 - Research and experimental development on biotechnology

incorporation date

May 2008

ultimate parent company

None

previous names

yprotech limited (November 2018)

yorkshire process technology limited (July 2015)

address

block 19 alderley park, mereside, alderley edge, cheshire, SK10 4TG

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We found 1 charges/mortgages relating to apex molecular limited. Currently there are 0 open charges and 1 have been satisfied in the past.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for APEX MOLECULAR LIMITED. This can take several minutes, an email will notify you when this has completed.

apex molecular limited Company Information

apex molecular limited Estimated Valuation

apex molecular limited Estimated Valuation

apex molecular limited Estimated Valuation

Apex Molecular Limited Overview

Apex Molecular Limited Health Check

APEX MOLECULAR LIMITED financials

apex molecular limited Credit Report and Business Information

Apex Molecular Limited Competitor Analysis

apex molecular limited Ownership

apex molecular limited directors

apex molecular limited company details

apex molecular limited Charges & Mortgages

apex molecular limited Capital Raised & Share Issues BETA

apex molecular limited Companies House Filings - See Documents